Circulating tumor cells as marker of poor prognosis in metastatic lung cancer: a pilot study
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1980-5578
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Circulating tumor cells as marker of poor prognosis in metastatic lung cancer: a pilot study ; volume:38 ; number:1 ; day:12 ; month:3 ; year:2018 ; pages:1-7 ; date:12.2018
Applied cancer research ; 38, Heft 1 (12.3.2018), 1-7, 12.2018
- Urheber
-
Diaz, Mônica Taiane de Macêdo
- Beteiligte Personen und Organisationen
-
Abdallah, Emne Ali
Tariki, Milena Shizue
Braun, Alexcia Camila
Dettino, Aldo Lourenço Abbade
Nicolau, Ulisses Ribaldo
Alves, Vanessa da Silva
Chinen, Ludmilla Thomé Domingos
SpringerLink (Online service)
- DOI
-
10.1186/s41241-018-0059-7
- URN
-
urn:nbn:de:1111-201804165917
- Rechteinformation
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:45 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Diaz, Mônica Taiane de Macêdo
- Abdallah, Emne Ali
- Tariki, Milena Shizue
- Braun, Alexcia Camila
- Dettino, Aldo Lourenço Abbade
- Nicolau, Ulisses Ribaldo
- Alves, Vanessa da Silva
- Chinen, Ludmilla Thomé Domingos
- SpringerLink (Online service)
Ähnliche Objekte (12)
PCPro: a clinically accessible, circulating lipid biomarker signature for poor-prognosis metastatic prostate cancer
Role of Circulating Tumor Cells in Determining Prognosis in Metastatic Breast Cancer
Liquid Biopsy for Prognosis and Treatment in Metastatic Colorectal Cancer: Circulating Tumor Cells vs Circulating Tumor DNA
Circulating tumor cells: a valuable marker of poor prognosis for advanced nasopharyngeal carcinoma
EpCAM-CD24+ circulating cells associated with poor prognosis in breast cancer patients
In patients with metastatic breast cancer the identification of circulating tumor cells in epithelial-to-mesenchymal transition is associated with a poor prognosis
CD133+CXCR4+ colon cancer cells exhibit metastatic potential and predict poor prognosis of patients
MET alterations detected in blood-derived circulating tumor DNA correlate with bone metastases and poor prognosis
Circulating NPTX2 methylation as a non-invasive biomarker for prognosis and monitoring of metastatic pancreatic cancer
Bone metastases in patients with metastatic renal cell carcinoma: are they always associated with poor prognosis?
Chromosome band 11q23 deletion predicts poor prognosis in bone marrow metastatic neuroblastoma patients without MYCN amplification
Overexpression in metastatic breast cancer supports Syndecan-1 as a marker of invasiveness and poor prognosis
PCPro: a clinically accessible, circulating lipid biomarker signature for poor-prognosis metastatic prostate cancer
Role of Circulating Tumor Cells in Determining Prognosis in Metastatic Breast Cancer
Liquid Biopsy for Prognosis and Treatment in Metastatic Colorectal Cancer: Circulating Tumor Cells vs Circulating Tumor DNA
Circulating tumor cells: a valuable marker of poor prognosis for advanced nasopharyngeal carcinoma
EpCAM-CD24+ circulating cells associated with poor prognosis in breast cancer patients
In patients with metastatic breast cancer the identification of circulating tumor cells in epithelial-to-mesenchymal transition is associated with a poor prognosis
CD133+CXCR4+ colon cancer cells exhibit metastatic potential and predict poor prognosis of patients
MET alterations detected in blood-derived circulating tumor DNA correlate with bone metastases and poor prognosis
Circulating NPTX2 methylation as a non-invasive biomarker for prognosis and monitoring of metastatic pancreatic cancer
Bone metastases in patients with metastatic renal cell carcinoma: are they always associated with poor prognosis?
Chromosome band 11q23 deletion predicts poor prognosis in bone marrow metastatic neuroblastoma patients without MYCN amplification
Overexpression in metastatic breast cancer supports Syndecan-1 as a marker of invasiveness and poor prognosis
PCPro: a clinically accessible, circulating lipid biomarker signature for poor-prognosis metastatic prostate cancer
Role of Circulating Tumor Cells in Determining Prognosis in Metastatic Breast Cancer
Liquid Biopsy for Prognosis and Treatment in Metastatic Colorectal Cancer: Circulating Tumor Cells vs Circulating Tumor DNA
Circulating tumor cells: a valuable marker of poor prognosis for advanced nasopharyngeal carcinoma
EpCAM-CD24+ circulating cells associated with poor prognosis in breast cancer patients
In patients with metastatic breast cancer the identification of circulating tumor cells in epithelial-to-mesenchymal transition is associated with a poor prognosis
CD133+CXCR4+ colon cancer cells exhibit metastatic potential and predict poor prognosis of patients
MET alterations detected in blood-derived circulating tumor DNA correlate with bone metastases and poor prognosis
Circulating NPTX2 methylation as a non-invasive biomarker for prognosis and monitoring of metastatic pancreatic cancer
Bone metastases in patients with metastatic renal cell carcinoma: are they always associated with poor prognosis?
Chromosome band 11q23 deletion predicts poor prognosis in bone marrow metastatic neuroblastoma patients without MYCN amplification